Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
25 hedge funds and large institutions have $71.4M invested in Sinovac Biotech, Ltd in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 0 closing their positions.
19% more funds holding
Funds holding: 21 → 25 (+4)
3% more capital invested
Capital invested by funds: $69.6M → $71.4M (+$1.79M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$12.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $38.2M | – | – | – |
|
|
O
2
OrbiMed
New York
| $27.3M | – | – | – |
|
|
NAH
3
Neumann Advisory (HK)
Central,
Hong Kong
| $2.04M | – | – | – |
|
4
Renaissance Technologies
New York
| $1.54M | – | – | – |
|
5
State Street
Boston,
Massachusetts
| $1.04M | – | – | – |
|
|
YMRC
6
Yorktown Management & Research Company
Forest,
Virginia
| $485K | – | – | – |
|
7
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
| $259K | – | – | – |
|
8
Geode Capital Management
Boston,
Massachusetts
| $179K | – | – | – |
|
|
FIM
9
Freedom Investment Management
Hartford,
Connecticut
| $121K | -$12.4K | -1,913 | -9% |
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $106K | – | – | – |
|
11
UBS Group
Zurich,
Switzerland
| $59K | – | – | – |
|
12
Northern Trust
Chicago,
Illinois
| $55K | – | – | – |
|
13
Morgan Stanley
New York
| $9K | – | – | – |
|
14
Group One Trading
Chicago,
Illinois
| $3K | – | – | – |
|
15
JP Morgan Chase
New York
| $3K | – | – | – |
|
SVA Hedge Fund Activity: Q3 2020 in Review
25 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2020, worth a combined $71.4M — up 2.6% from $69.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SVA positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 3 trimmed.
The largest seller was Freedom Investment Management, cutting an estimated $12.4K.
- 25 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2020, up from 21 in Q2 2020.
- Funds reported $71.4M of Sinovac Biotech, Ltd stock for Q3 2020, up 2.6% quarter-over-quarter.
- 4 funds opened new Sinovac Biotech, Ltd positions in Q3 2020 and 0 closed out, a net change of +4 holders.
- The largest Sinovac Biotech, Ltd seller in Q3 2020 was Freedom Investment Management, an estimated $12.4K sold.
Based on aggregated 13F filings for Q3 2020.